stockrowCareDx, Inc.
CDNA Healthcare Diagnostics & Research
CareDx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $379.8 million, up 13.8% from fiscal 2024.
- Revenue
- +39.3%
- EPS
- +1,133.3%
- Free cash flow
- −68.6%
Quarter to September 2026, against a year earlier
Follow CDNA
Alert me
CareDx, Inc. (CDNA) Return on invested capital
CareDx, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 33.6%, up 48.8 percentage points from fiscal 2025 (−15.3%). Over the past ten years it has ranged from −490.6% (fiscal 2023) to 21.6% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −15.3% | (36.91) |
| FY2024 | 21.6% | 512.18 |
| FY2023 | −490.6% | (455.53) |
| FY2022 | −35.0% | (19.19) |
| FY2021 | −15.8% | 10.75 |
| FY2020 | −26.6% | (1.35) |
| FY2019 | −25.2% | 5.86 |
| FY2018 | −31.1% | 82.06 |
| FY2017 | −113.2% | (24.93) |
| FY2016 | −88.2% | (39.67) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CDNA CareDx, Inc. | 33.6% |
| SHC Sotera Health Company compare | 9.80% |
| VCYT Veracyte, Inc. compare | 4.33% |
| RDNT RadNet, Inc. compare | 2.24% |
| ADPT Adaptive Biotechnologies Corporation compare | 0.00% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| NEO NeoGenomics, Inc. compare | −2.97% |
| GRAL GRAIL, Inc. compare | −14.7% |
| WGS GeneDx Holdings Corp. compare | −27.7% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on CDNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement